Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Vanderbilt-Ingram Cancer Center: Clinical Trials & FDA Approval Profile

Vanderbilt-Ingram Cancer Center (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 9 active protocols (8 recruiting now), 2 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)29.4%
Median Closed Enrollment vs National (145 pts)12 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Vanderbilt-Ingram Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)9 (8)
Completed vs Stopped Early2 / 5 (29.4%)
Median Closed Actual Enrollment12 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Vanderbilt-Ingram Cancer Center
Hospital Research SiteLocationShared Protocols
Vanderbilt University Medical CenterNashville, TN16
Emory Winship Cancer InstituteAtlanta, GA2

Explore interactive annual charts and M&A subsidiary rollups in the Vanderbilt-Ingram Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI